An interventional study of Virtual reality in Alzheimer Disease and Memory Disorders, sponsored by Universidad de Burgos. Completed at 1 site in Spain. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Universidad de Burgos · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 222nd largest by enrollment of the 240 interventional ones that give a count, is one of 21 that started in 2025, is one of 66 with no phase, and was the 272nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Universidad de Burgos is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Universidad de Burgos has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate whether immersive virtual reality (VR) can improve cognitive function and memory in patients with Alzheimer's disease. Twenty participants in Burgos, Spain, will engage in VR sessions that recreate scenes from 1960s Burgos, representing environments familiar from the participants' youth. The effects of these VR-based cognitive stimulation sessions will be assessed through pre- and post-intervention evaluations, including behavioral observations, EEG monitoring of brain activity, and standardized neurocognitive tests (Montreal Cognitive Assessment, Clock-Drawing Test, and Verbal Fluency Test).
Introduction: Alzheimer's disease is a neurodegenerative condition characterized by progressive cognitive decline. Virtual reality (VR) technologies offer an innovative approach to cognitive stimulation in patients with this condition. This study will evaluate the impact of VR on memory and cognition improvement in patients with Alzheimer's disease in Burgos.
Objective: Evaluate the effectiveness of cognitive and memory stimulation through virtual reality experiences in patients with Alzheimer's disease, using behavioral analysis, biometric data (EEG), and neurocognitive testing.
Methodology: A total of 20 patients diagnosed with Alzheimer's disease at a specialized center in Burgos will be selected. The patients will be exposed to virtual reality scenarios recreating the city of Burgos in the 1960s, a period corresponding to their youth. Their cognitive and emotional status will be assessed before and after the sessions using neurocognitive tests, behavioral monitoring, and biometric data recording (EEG). Analyses of variance (ANOVA), analyses of covariance (ANCOVA), and multivariate analyses of variance (MANOVA) were perfomed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The sample consisted of 33 people: 16 in the experimental group.
Other: Virtual reality
The sample consisted of 33 people: 17 in the control group.
The intervention consists of a series of immersive virtual reality (VR) sessions designed to provide cognitive stimulation for patients diagnosed with Alzheimer's disease. Participants in the experimental group will be exposed to VR environments that recreate the city of Burgos as it appeared in the 1960s, an era corresponding to their youth. These VR experiences will include familiar scenes, landmarks, and culturally relevant settings designed to evoke personal memories and enhance cognitive engagement.
Change in Cognitive Function (Montreal Cognitive Assessment - MoCA)
Change in cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates multiple cognitive domains, including memory, attention, language, executive function, and visuospatial abilities. Total scores range from 0 to 30, with higher scores indicating better cognitive function. The change score will be calculated as the post-intervention score minus the baseline score.
Time frame: Baseline and immediately after the last virtual reality session
Change in emotional well-being assessed with the Satisfaction With Life Scale (SWLS)
Change in emotional well-being will be assessed using the Satisfaction With Life Scale (SWLS). The SWLS is a 5-item scale that assesses global life satisfaction. Total scores range from 5 to 35, with higher scores indicating greater satisfaction with life and better emotional well-being. The change score will be calculated as the post-intervention score minus the baseline score.
Time frame: Baseline and immediately after the last virtual reality session
Change in Verbal Fluency (Verbal Fluency Test)
Change in the number of words generated in a 60-second period, assessing language and cognitive processing speed.
Time frame: Baseline and post-intervention.
Change in attention and processing speed
Attention, visual scanning, and processing speed will be assessed using the Trail Making Test Part A. The outcome will be the time required to complete the task. Lower completion times indicate better performance.
Time frame: Baseline and immediately after the last virtual reality session
Change in executive function and cognitive flexibility assessed with the Trail Making Test Part B (TMT-B)
Executive function and cognitive flexibility will be assessed using the Trail Making Test Part B. The outcome will be the time required to complete the task. Lower completion times indicate better performance.
Time frame: Baseline and immediately after the last virtual reality session
Change in positive affect assessed with the Positive and Negative Affect Schedule Short Form (PANAS-S)
Positive affect will be assessed using the positive affect subscale of the Positive and Negative Affect Schedule Short Form (PANAS-S). Higher scores indicate greater positive affect.
Time frame: Baseline and immediately after the last virtual reality session.
Change in negative affect assessed with the Positive and Negative Affect Schedule Short Form (PANAS-S)
Negative affect will be assessed using the negative affect subscale of the Positive and Negative Affect Schedule Short Form (PANAS-S). Higher scores indicate greater negative affect.
Time frame: Baseline and immediately after the last virtual reality session
Immediate emotional response assessed with an Emotional Visual Analog Scale
Immediate emotional response will be assessed after each intervention session using an Emotional Visual Analog Scale ranging from 0 to 10, where higher scores indicate a more positive emotional state.
Time frame: Baseline and immediately after the last virtual reality session
Plan to share: No
Ran from Jan 2025 to primary completion in Mar 2025, 2 months.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 2 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de Burgos